Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013

 

London, UK (November 22, 2013) – This press release provides an overview of the opinions adopted at the November 2013 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.

 

 

Seven medicines recommended for approval

 

The CHMP recommended granting a marketing authorisation for Sovaldi (sofosbuvir) in combination with other medicines for the treatment of chronic (long-term) hepatitis C in adults. Please see press release for more information.

 

The CHMP recommended the approval of Tivicay in combination with other anti-retroviral medicines for the treatment of adults and adolescents over 12 years of age infected with human immunodeficiency virus (HIV). Please see press release for more information.

 

The CHMP recommended marketing authorisations for two tuberculosis medicines. One is Deltyba (delamanid), which is recommended for the treatment of pulmonary infections due to multidrug-resistant tuberculosis; the other is Para-aminosalicylic acid Lucane, recommended for the treatment of multidrug-resistant tuberculosis. Both are orphan medicines. Please see press release for more information.

 

The Committee also recommended the granting of a marketing authorisation for Xigduo for the treatment of type 2 diabetes.

 

The Committee gave a positive recommendation for Cholic Acid FGK for the treatment of inborn errors of primary bile acid synthesis. Cholic Acid FGK is an orphan medicine.

 

The generic medicine Zoledronic Acid Accord also received a positive opinion for use in the prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.

 

 

Update of previous Tecfidera opinion

 

The CHMP has updated its previous opinion and agreed that dymethil fumarate in Tecfidera is qualified as a new active substance. More information will be made available in a summary of opinion shortly.

 

 

Negative opinion for Masican

 

The Committee adopted a negative opinion for the orphan medicine Masican, which was intended for the treatment of gastrointestinal stromal tumour.

 

 

Three recommendations on extensions of therapeutic indications

 

The CHMP recommended adding the treatment of patients with metastatic pancreatic cancer to the approved indications for Abraxane. Please see press release for more details.

The Committee also recommended extensions of indications for Pradaxa and Velcade.

 

 

New compassionate-use programme

 

The CHMP has given an opinion on the use of daclatasvir in combination with sofosbuvir in the treatment of chronic (long-term) hepatitis C virus infection, in a compassionate-use programme. More information is available in a separate press release.

 

 

Outcome of combined hormonal contraceptives safety review

 

The CHMP has completed its review of combined hormonal contraceptives (CHCs). The CHMP endorsed the October 2013 recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) that the benefits of CHCs in preventing unwanted pregnancies continue to outweigh their risks, and that the well-known risk of VTE with all CHCs is small. The review reinforced the importance of ensuring that clear and up-to-date information is provided to women who use these medicines and to the healthcare professionals giving advice and clinical care.

 

 

Outcome of safety review of thiocolchicoside-containing medicines      

 

In addition to the safety review on CHCs, the Committee also issued recommendations on thiocolchicoside-containing medicines.

 

 

Update on Iclusig

 

The CHMP made a number of recommendations intended to minimise the risk of blood clots obstructing the arteries and veins in patients taking the leukaemia medicine Iclusig. The recommendations follow a review of data from two ongoing clinical trials indicating that blood clots were occurring at a higher rate than was observed at the time of the medicine’s initial authorisation.

 

More information on these and all other outcomes of this month’s meeting are available on the Agency’s website at:

 

 


 

European Medicines Agency, 22.11.2013. (tB)

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung